TLR7 and neoplasm: In view of the above, we developed a drug delivery system that can homologously target tumor sites for the combined delivery of a TLR7/8 agonist and BET inhibitor to trigger effective antitumor immunotherapy for TNBC, achieving the combined effect of tumor-targeted delivery of epigenetic drugs and immune checkpoint blockade.